Pα+ Psychedelic Bulletin #218: FDA’s Farchione Says Psychedelic INDs Are “a Third” of Her Workload; Ipsos/Psychedelic Alpha Poll; Phase 3 Plans

FDA psychiatry official Tiffany Farchione says psychedelic IND reviews now make up about a third of her workload, framing growing regulatory activity alongside NIDA director questions about Schedule I placement. The bulletin also summarizes public-attitude research from an Ipsos and Psychedelic Alpha poll, plus RAND estimates that roughly 10 million US adults microdosed in the prior year. On drug development, the bulletin highlights Reunion Medicine’s push for a single Phase 3 pathway in PPD and its release of additional Phase 2 data, and it notes MindMed’s rebrand to Definium with an LSD education push. It additionally includes an interview focused on an independent psychedelic evidence assessment working group and mentions policy movement such as a New Jersey psilocybin pilot program law.